{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:58:43Z","timestamp":1785862723313,"version":"3.56.0"},"reference-count":38,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T00:00:00Z","timestamp":1476057600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006970","name":"Ikaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,10]]},"abstract":"\n Aims<\/jats:title>\n \n To compare effects of basal insulin peglispro (\n BIL<\/jats:styled-content>\n ), a hepatopreferential insulin, to insulin glargine (glargine) on aminotransferases and liver fat content (\n LFC<\/jats:styled-content>\n ) in patients with type 1 and type 2 diabetes (\n T1D<\/jats:styled-content>\n ,\n T2D<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n \n Data from two Phase 2 and five Phase 3 randomized trials comparing\n BIL<\/jats:styled-content>\n and glargine in 1709\n T1D<\/jats:styled-content>\n and 3662\n T2D<\/jats:styled-content>\n patients were integrated for analysis of liver laboratory tests.\n LFC<\/jats:styled-content>\n , measured by magnetic resonance imaging (\n MRI<\/jats:styled-content>\n ) at baseline, 26 and 52 weeks, was analyzed in 182\n T1D<\/jats:styled-content>\n patients, 176 insulin\u2010na\u00efve\n T2D<\/jats:styled-content>\n patients and 163\n T2D<\/jats:styled-content>\n patients previously treated with basal insulin.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Alanine aminotransferase (\n ALT<\/jats:styled-content>\n ) increased in patients treated with\n BIL<\/jats:styled-content>\n , was higher than in glargine\u2010treated patients at 4\u201078 weeks (difference at 52 weeks in both\n T1D<\/jats:styled-content>\n and\n T2D<\/jats:styled-content>\n : 7 international units\/litre (\n IU<\/jats:styled-content>\n \/L),\n P<\/jats:italic>\n \u2009<\u2009.001), and decreased after discontinuation of\n BIL<\/jats:styled-content>\n . More\n BIL<\/jats:styled-content>\n patients had\n ALT<\/jats:styled-content>\n \u2265\n 3\u00d7<\/jats:styled-content>\n upper limit of normal (\n ULN<\/jats:styled-content>\n ) than glargine. No patient had\n ALT<\/jats:styled-content>\n \u2265\n 3\u00d7 ULN<\/jats:styled-content>\n with bilirubin \u2265\n 2\u00d7 ULN<\/jats:styled-content>\n that was considered causally related to\n BIL<\/jats:styled-content>\n . In insulin\u2010na\u0457ve\n T2D<\/jats:styled-content>\n patients,\n LFC<\/jats:styled-content>\n decreased with glargine but was unchanged with\n BIL<\/jats:styled-content>\n . In\n T1D<\/jats:styled-content>\n and\n T2D<\/jats:styled-content>\n patients previously treated with basal insulin,\n LFC<\/jats:styled-content>\n was unchanged with glargine but increased with\n BIL<\/jats:styled-content>\n . In all three populations,\n LFC<\/jats:styled-content>\n was higher after treatment with\n BIL<\/jats:styled-content>\n vs glargine (difference at 52 weeks: 2.2% to 5.3%, all\n P<\/jats:italic>\n \u2009<\u2009.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Compared to glargine, patients treated with\n BIL<\/jats:styled-content>\n had higher\n ALT<\/jats:styled-content>\n and\n LFC<\/jats:styled-content>\n at 52\u201078 weeks. No severe drug\u2010induced liver injury was apparent with\n BIL<\/jats:styled-content>\n treatment for up to 78 weeks.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12751","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T06:39:20Z","timestamp":1476340760000},"page":"50-58","source":"Crossref","is-referenced-by-count":33,"title":["Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes"],"prefix":"10.1111","volume":"18","author":[{"given":"K.","family":"Cusi","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism University of Florida College of Medicine Gainesville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine Virginia Commonwealth University Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Hoogwerf","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Chang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Jacober","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Bue\u2010Valleskey","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"Higdon","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"E. J.","family":"Bastyr","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"},{"name":"Indiana University School of Medicine Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haupt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Lilly Corporate Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-013-9480-x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3050"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1966"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07486.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00133.2006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2007.02.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e3182621c5f"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-014-0638-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2548"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.276"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12222"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0210"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1531"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12698"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12696"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12712"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12738"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12757"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0067"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0060"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.23928"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.07.014"},{"key":"e_1_2_6_24_1","unstructured":"Food and Drug Administration (FDA). Guidance for industry drug\u2010induced liver injury: Premarketing clinical evaluation.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf. Accessed May 4 2016."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00064.2004"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27395"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02312"},{"key":"e_1_2_6_28_1","unstructured":"Mircera. Summary of product characteristics.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000739\/WC500033672.pdf. Accessed May 4 2016."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12117"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(11)70014-6"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27073"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1423952112"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0826"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12753"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0266"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12754"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.003"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1876"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1539"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12751","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:52:01Z","timestamp":1761864721000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/dom.12751"],"URL":"https:\/\/doi.org\/10.1111\/dom.12751","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}